Details for Patent: 8,354,430
✉ Email this page to a colleague
Which drugs does patent 8,354,430 protect, and when does it expire?
Patent 8,354,430 protects WAKIX and is included in one NDA.
This patent has twenty-seven patent family members in twenty-one countries.
Summary for Patent: 8,354,430
| Title: | Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine |
| Abstract: | A method is provided for the treatment of sleep apnea and other conditions wherein an effective amount of crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride of formula (I): optionally comprising water up to 6%, and having an X-ray diffractogram that comprises characteristic peaks (2θ) at 11.2°, 19.9°, 20.7° and 34.1°±0.2° is administered to a patient in need thereof. |
| Inventor(s): | Manuel Raga, Juan Sallares, Marta Guerrero, Antonio Guglietta, Jean-Michel Arrang, Jean-Charles Schwartz, Holger Stark, Walter Schunack, Xavier Ligneau, Jeanne-Marie Lecomte, Charon Ganellin |
| Assignee: | Bioprojet SC |
| Application Number: | US13/491,229 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,354,430 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,354,430
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harmony | WAKIX | pitolisant hydrochloride | TABLET;ORAL | 211150-001 | Aug 14, 2019 | RX | Yes | No | 8,354,430 | ⤷ Start Trial | METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY | ⤷ Start Trial | ||||
| Harmony | WAKIX | pitolisant hydrochloride | TABLET;ORAL | 211150-001 | Aug 14, 2019 | RX | Yes | No | 8,354,430 | ⤷ Start Trial | METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY | ⤷ Start Trial | ||||
| Harmony | WAKIX | pitolisant hydrochloride | TABLET;ORAL | 211150-002 | Aug 14, 2019 | RX | Yes | Yes | 8,354,430 | ⤷ Start Trial | METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY | ⤷ Start Trial | ||||
| Harmony | WAKIX | pitolisant hydrochloride | TABLET;ORAL | 211150-002 | Aug 14, 2019 | RX | Yes | Yes | 8,354,430 | ⤷ Start Trial | METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,354,430
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 05100942 | Feb 10, 2005 | |
International Family Members for US Patent 8,354,430
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 054734 | ⤷ Start Trial | |||
| Austria | E391716 | ⤷ Start Trial | |||
| Austria | E402154 | ⤷ Start Trial | |||
| Canada | 2597016 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
